Articles tagged with Cachexia
Researchers discovered specific microRNAs, including miR-16 and miR-140, which may help detect cancer-related muscle wasting in dogs. The study's findings have implications for human medicine, suggesting a potential new approach for earlier diagnosis and monitoring of cancer-related cachexia.
A new study reveals that lung tumors can cause cachexia by hacking into the nervous system and altering eating behavior. Researchers found that tumors missing a gene called LKB1 produced prostaglandin E2, a signaling molecule that amplifies inflammation and causes weight loss.
A new study by Thales Papagiannakopoulos and colleagues found that lung cancer tumors talk directly to the nervous system through sensory neurons in the lungs, promoting cachexia. Silencing these nerves or blocking the production of prostaglandin E2 (PGE2) reduced cachexia, suggesting a potential therapeutic strategy.
Cancer cell researchers at the University of Oklahoma have developed a novel 'triangle regulation theory' that explains the development of cancer-induced cachexia and anorexia. The theory reveals how cancer cells recruit immune cells to trigger excess production of growth factor 15, leading to muscle wasting and loss of appetite.
Researchers at the University of Houston have discovered a potential therapeutic strategy for counteracting muscle wasting in pancreatic cancer by blocking a specific cell pathway. Muscle wasting, also known as cachexia, is a debilitating syndrome affecting 60-85% of patients with pancreatic cancer.
Alex Arreola, a University of Oklahoma health doctoral student, has received a National Cancer Institute grant to investigate the mechanisms behind cancer cachexia, a severe weight loss syndrome prevalent in pancreatic cancer patients. He aims to understand how tumors promote early-stage weight loss and explore potential treatments.
Cachexia affects connections between brain and immune system, reducing motivation in cancer patients. Patient-reported symptoms are invaluable data points that may help researchers better understand disease progression.
Researchers discovered that disrupted brain-liver communication due to vagus nerve dysregulation leads to damage in liver metabolism and cachexia development. Targeted blocking of the right vagus nerve prevents cachexia's development, enhances chemotherapy response, and improves overall health and survival in mice.
Researchers at Helmholtz Munich discovered that liver metabolism is reprogrammed in cachexia, with a specific gene called REV-ERBα being almost completely shut down. This 'internal clock' regulates liver-derived signaling molecules that drive disease progression and promote physical wasting.
A new AI-driven biomarker model analyzes imaging and clinical data to predict cancer cachexia with high accuracy, improving detection rates by up to 85% compared to standard methods. The model's skeletal muscle quantification function was trained using annotated CT scans and validated on a separate set of images.
Researchers at Cold Spring Harbor Laboratory have identified a connection between the brain and immune system responsible for cachexia-related apathy. By targeting specific neurons and immune system proteins, they hope to improve cancer patients' quality of life and tolerance for treatments.
A study published in Science discovered a direct connection between cancer-related inflammation and the loss of motivation characteristic of advanced cancer. Blocking the inflammatory pathway restored motivation in mice with cachexia, suggesting a potential treatment for apathy associated with chronic illnesses.
Researchers developed nanoparticles to deliver anti-inflammatory agents across the blood-brain barrier, opening new possibilities for treating Alzheimer's disease and other brain-related disorders. The delivery method successfully reduced inflammatory markers and improved food intake in mice with cancer cachexia.
Scientists have discovered a potential new treatment strategy for pancreatic cancer by identifying the molecule Neuropeptide Y (NPY) as a key driver of its spread. Blocking NPY's function has been shown to reduce cancer cell movement and metastatic outgrowth, potentially limiting disease progression.
A new study from the Salk Institute has discovered that a protein called BCL6 plays a crucial role in maintaining healthy muscle mass. Increasing BCL6 levels successfully reversed muscle losses in mice, suggesting that pairing GLP-1 medications with a BCL6-boosting drug could help counteract unwanted muscle loss.
Min Li will receive the 2024 Palade Prize for his contributions to pancreatology, recognizing his pioneering work on pancreatic cancer and metabolic reprogramming. He has been continuously funded by the National Cancer Institute for 15 years and has published over 200 high-impact articles.
A new study from Japan confirms that definitive criteria for lower cachexia prevalence rates are linked to reduced survival rates in cancer patients. The study found that the diagnostic criteria used for cachexia detection can affect reported prevalence and survival outcomes, emphasizing the need for accurate diagnosis.
Researchers found that physically fitter patients with metastatic lung cancer live longer and respond better to chemotherapy. The study identified biomarkers in blood plasma that can indicate which patients are most likely to respond to treatment.
The 'MiCCrobioTAckle' project investigates the complex interactions between the gut microbiome and tumor cachexia to find ways of slowing down muscle breakdown. Twelve doctoral researchers from twelve countries will work together across Europe, gaining new insights into the relationship between the gut microbiome and cancer cachexia.
Researchers found that maintaining optimal levels of DEAF1 is crucial for muscle repair and regeneration, and that restoring balance with DEAF1 may counteract some effects of aging on muscle tissue. This could lead to improved treatments for sarcopenia and cachexia, conditions affecting millions of older adults and cancer patients.
Researchers discovered ponsegromab, a monoclonal antibody, improves symptoms of cachexia by blocking the GDF-15 hormone. The treatment shows minimal side effects and boosts weight gain and patient activity in cancer patients.
Researchers have found that blocking Interleukin-6 (IL-6) from binding to neurons in the area postrema prevents cachexia in mice. This breakthrough discovery could lead to the development of new drugs targeting these neurons, potentially treating cancer cachexia and improving patients' quality of life.
A new study reveals that 'crosstalk' between pancreatic cancer cells and macrophages is the first step towards the onset of cachexia. The research provides evidence of an underlying mechanism for the development of this debilitating muscle-wasting condition, which affects pancreatic cancer patients.
A University of Oklahoma researcher has made promising discoveries on the role of vitamin B6 in pancreatic cancer. By understanding how pancreatic cancer cells deplete vitamin B6, she developed a three-part strategy to impede their growth and enhance immune function.
A study by researchers from Osaka University found that HSP47, a collagen-specific molecular chaperone, is significantly expressed in fat tissue and correlates with body fat levels. High or low HSP47 expression was linked to high or low body fat levels in both humans and mice.
Researchers have identified KIAA0930 as a key factor causing muscle atrophy in cancer cells, which could lead to the development of new anti-cachexia therapies. The study found that KIAA0930 knockdown cells showed increased muscle mass and weight compared to control cells.
A keto diet may help reduce body weight and slow tumor growth in cancer patients. However, research found that this diet can cause early-onset cachexia, a lethal wasting disease, in mice with pancreatic and colorectal cancer. Pairing keto with corticosteroids prevented cachexia in mice, allowing them to live longer.
Researchers at Koc University have identified a novel molecular mechanism that can slow down or block muscle wasting in cancer patients. The activation of EDA2R signalling promotes skeletal muscle atrophy, and deleting either EDA2R or NIK enzyme can protect the organism from muscle loss.
Researchers developed a predictive model to identify tumor biomarkers of cachexia in lung cancer patients. The study used machine learning to build a muscle loss prediction model based on muscularity, clinical data, and the transcriptional profile from the tumor microenvironment.
Researchers at MIT developed an ingestible capsule that delivers electrical stimulation to the stomach, boosting ghrelin production and potentially alleviating nausea and appetite loss. The device uses a grooved surface to create a drier environment for electrodes to contact stomach tissue.
Researchers at NUS found that vesicles released by red blood cells can deliver RNA-based drugs to increase muscle growth and suppress cancer-associated skeletal muscle weakening. The study showed improved efficacy compared to traditional delivery methods without inducing toxicity or inflammatory reactions.
Researchers have identified a key enzyme in muscle that contributes to cancer-induced muscle wasting. Targeting this enzyme, UBR2, may help preserve muscle mass and function in cancer patients. The study's findings offer new hope for the treatment of cancer cachexia, a complication affecting 60% of all cancer patients.
A global team led by Rutgers Cancer Institute of New Jersey has secured $25 million to study cachexia, a debilitating wasting condition responsible for up to 30% of cancer deaths. The team plans to build a deep understanding of what causes cachexia and develop novel treatments.
A new study found that exercising before developing cancer reduced tumor growth and cachexia symptoms in mice. Regular exercise improved cardiac structure and function, and helped slow tumor growth even after cancer was induced.
A new study confirms that abnormalities in the GDF15 gene are involved in hyperemesis gravidarum, a condition causing severe nausea and vomiting during pregnancy. The discovery may lead to targeted treatments and improved care for women with HG.
The International Lipid Expert Panel recommends a step-by-step approach to diagnosing and managing muscle symptoms caused by statins. The 'nocebo/drucebo' effect, where patients experience side effects due to expectation, affects up to 70% of diagnosed statin intolerance cases.
Researchers found that iron supplementation can sustain muscle function, mass, and survival in mouse models of colon cancer. In humans, a small group experienced moderate strength improvement after iron injection, suggesting potential benefits for cachexia sufferers.
The MUSC Hollings Cancer Center researchers are exploring the role of macroenvironment in pancreatic cancer-induced cachexia to address this debilitating condition. The team aims to provide new biological insight, which will be coordinated by four cores within the program project grant.
Cachexia is characterized by weight loss and muscle tissue shrinkage, driven by the immune system's response to chronic infections and diseases. Researchers from CeMM emphasize the need for more research into cachexia, highlighting the importance of interplay between the immune system and metabolism.
Researchers at UC Berkeley found that tumors release chemicals compromising the blood-brain barrier, leading to inflammation and tissue wasting. Blocking these chemicals could extend life span and improve health for cancer patients, reducing the need for toxic drugs.
Researchers used a mouse cachexia model to investigate myocardial damage in tumor-bearing mice, finding suppressed oxidative phosphorylation and glycolysis. The study validates the model for studying cancer-derived myocardial impairment, revealing various changes associated with cancer cachexia.
Researchers in Brazil identified a gene expression profile associated with cachexia, a potentially fatal syndrome characterized by severe weight loss and muscle wasting. The study found that pancreatic, esophageal, colorectal, stomach, and head-and-neck cancers are most frequently linked to cachexia.
A new mouse model called KPP better mimics human cachexia symptoms, allowing researchers to control when cancer can be triggered. This advancement could lead to novel discoveries and identification of therapeutic targets for this devastating syndrome.
A researcher at Oregon State University has received a $2.3 million grant to develop an effective treatment for cachexia, a muscle-wasting syndrome that kills up to 30% of cancer patients. The new research aims to preserve muscle mass and reduce death and suffering among patients with various cancers.
Researchers from the University of Oklahoma College of Medicine have identified ZIP4 as the trigger for muscle-wasting cachexia in pancreatic cancer. By inhibiting ZIP4, they hope to prevent cachexia and improve treatment outcomes for patients with pancreatic cancer.
Chronic viral infections trigger cachexia through reorganized fat tissue and CD8 T cells, contrary to expectations.
Researchers have discovered that atorvastatin, a drug typically used to control cholesterol, can also treat cachexia, a condition characterized by rapid weight loss and muscle atrophy. In mouse studies, treatment with atorvastatin attenuated adipose tissue remodeling, leading to rapid weight loss and muscle atrophy.
A new study from the European Society of Cardiology found that loss of muscle mass is a significant risk factor for disability after stroke. Muscle wasting was observed in patients who lost at least 5% of their body weight, and those with cachexia had lower functional capacity and handgrip strength.
Researchers at Texas A&M University found that testosterone treatment can help combat cachexia, a syndrome characterized by rapid or severe loss of fat and skeletal muscle, in cancer patients. Patients treated with testosterone maintained total body mass and increased lean body mass, allowing them to perform daily activities more easily.
A new study from Columbia University Irving Medical Center suggests that excess zinc in muscles contributes to cachexia, a debilitating muscle-wasting syndrome affecting 80% of advanced cancer patients. The discovery could pave the way for developing drugs to treat or prevent muscle wasting in cancer patients.
Cachexia, a condition characterized by weight loss and muscle atrophy in cancer patients, is responsible for over 30% of deaths. Researchers aim to reverse this condition through novel treatments involving febuxostat, beta-blockers, and gut microbiome transplantation.
A new study aims to save lives by giving doctors a practical tool to diagnose cachexia in cancer patients. Cachexia is characterized by muscle wasting and metabolic changes, affecting patient prognosis and quality of life.
Researchers have identified AMPK as the central enzyme in cancer cachexia, a condition that results in weight loss due to metabolic complications. A peptide was developed to selectively reactivate AMPK, which has been shown to prevent increased fat breakdown and promote 'healthy' adipose tissue.
A study published in PLOS Medicine found that low body mass index increases risk of mortality after acute myocardial infarction, even after controlling for other health factors. The researchers analyzed data from 57,574 elderly patients and found underweight patients had a 13-26% higher risk of death compared to normal weight patients.
Researchers have deciphered a new molecular signaling pathway that promotes muscle loss in heart failure patients. The study found that suppressing this pathway may inhibit muscle atrophy, offering high potential for therapeutic options.
Two independent studies reveal that tumor-secreted molecule ImpL2 causes wasting syndrome, also known as cachexia, in fly cancer models. Researchers found that depletion of ImpL2 levels significantly reduced wasting in flies, suggesting new candidates for mediators of cachexia and novel therapeutic approaches.
Research reveals that white fat transforming into brown fat may stimulate weight gain and muscle strength in cancer patients suffering from cachexia. The browning process is triggered by inflammation, and anti-inflammatory therapies show promise in alleviating the condition.
Researchers have found that cachexia, associated with cancer, is triggered by the conversion of white fat to brown fat tissue, a process also studied for obesity and diabetes. Blocking inflammation-promoting cytokine IL-6 can reduce cachexia symptoms.
A new study has identified a molecular cause of cachexia and suggests a potential treatment using an anti-PTHrP antibody. The research found that blocking the effects of PTHrP can prevent wasting and improve muscle mass in mice with lung tumors.
A study by Concordia University and McGill University Health Centre found a strong link between muscle mass and strength in cancer patients with severe fatigue. The researchers suggest that specialized strength training programs could improve muscle mass and reduce fatigue, enhancing the quality of life for these patients.